The purpose of the Administration, Communication, and Planning Core is to assure the coordination ofthe Dana Farber/Harvard Cancer Center (DF/HCC) Myeloma SPORE components and to provide oversightand leadership of the scientific, administrative, and fiscal aspects of the SPORE. The SPORE Director willoversee the administrative coordination of the various clinical and laboratory studies outlined in this Program.He will integrate scientific and clinical efforts within and between Projects, and assure the translation oflaboratory findings to the bedside; and conversely, the initiation of laboratory studies stemming from clinicalobservations.During the prior funding period, the infrastructure has been created to have seemless communicationand exchange of data between SPORE sites, facilitating collaborative preclinical studies and clinical trials.Multiple joint publications, completed and ongoing clinical trials, and the translation of several novel targetedtherapies from bench to bedside confirm the communication and integration of our efforts. This Core willcontinue to facilitate exchange of information among the SPORE members, as well as the internal andexternal advisory committees. It will provide clinical research nursing support for the proposed clinical trials.In addition, as in the previous funding period, a clinical study coordinator will assure appropriate sampleacquisition and trafficking. The grants administrator will allocate resources in a timely and integrated fashionto facilitate successful completion of the proposed studies.
The Specific Aims of the Administration,Communication, and Planning Core are to:1. Monitor research progress and plan for the future;i2. Foster collaborative research within the SPORE and between SPOREs;3. Integrate the Myeloma SPORE into the DF/HCC structure;4. Provide necessary resources and fiscal oversight; and5. Promote rapid dissemination of significant research finding

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100707-06
Application #
7507325
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-08-31
Support Year
6
Fiscal Year
2008
Total Cost
$145,058
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Bolli, Niccolò; Maura, Francesco; Minvielle, Stephane et al. (2018) Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9:3363
Gullà, A; Hideshima, T; Bianchi, G et al. (2018) Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia 32:996-1002
Mazzotti, Céline; Buisson, Laure; Maheo, Sabrina et al. (2018) Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv 2:2811-2813
Samur, Mehmet Kemal; Minvielle, Stephane; Gulla, Annamaria et al. (2018) Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia 32:2626-2635
Xu, Yan; Deng, Shuhui; Mao, Xuehan et al. (2018) Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk 18:422-430
Michallet, M; Chapuis-Cellier, C; Dejoie, T et al. (2018) Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia 32:376-382
Ray, A; Das, D S; Song, Y et al. (2018) Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia 32:843-846
Guang, Matthew Ho Zhi; McCann, Amanda; Bianchi, Giada et al. (2018) Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma 59:542-561
Perrot, Aurore; Lauwers-Cances, Valerie; Corre, Jill et al. (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132:2456-2464
Tai, Yu-Tzu; Lin, Liang; Xing, Lijie et al. (2018) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia :

Showing the most recent 10 out of 407 publications